In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.

Example Input: SECTION 1. PUBLIC HEALTH SERVICE ACT; LIABILITY PROTECTIONS FOR HEALTH-
              CENTER PRACTITIONERS PROVIDING SERVICES IN EMERGENCY 
              AREAS.

    (a) In General.--Section 224(g) of the Public Health Service Act 
(42 U.S.C. 233(g)) is amended--
            (1) in paragraph (1)(B)(ii), by striking ``subparagraph 
        (C)'' and inserting ``subparagraph (C) and paragraph (6)''; and
            (2) by adding at the end the following paragraph:
    ``(6)(A) Subject to subparagraph (C), paragraph (1)(B)(ii) applies 
to health services provided to individuals who are not patients of the 
entity involved if, as determined under criteria issued by the 
Secretary, the following conditions are met:
            ``(i) The services are provided by a contractor or employee 
        of the entity who is a physician or other licensed or certified 
        health care practitioner and who is otherwise deemed to be an 
        employee for purposes of paragraph (1)(A) when providing 
        services with respect to the entity.
            ``(ii) The services are provided in an emergency area (as 
        defined in subparagraph (D)).
            ``(iii) The services of the contractor or employee 
        (referred to in this paragraph as the `out-of-area 
        practitioner') are provided under an arrangement with--
                    ``(I) an entity that is deemed to be an employee 
                for purposes of paragraph (1)(A) and that serves the 
                emergency area involved (referred to in this paragraph 
                as an `emergency-area entity)'; or
                    ``(II) a Federal agency that has responsibilities 
                regarding the provision of health services in such area 
                during the emergency.
            ``(iv) The purposes of the arrangement are--
                    ``(I) to coordinate, to the extent practicable, the 
                provision of health services in the emergency area by 
                the out-of-area practitioner with the provision of 
                services by the emergency-area entity, or by the 
                Federal agency, as the case may be;
                    ``(II) to identify a location in the emergency area 
                to which such practitioner should report for purposes 
                of providing health services, and to identify an 
                individual or individuals in the area to whom the 
                practitioner should report for such purposes; and
                    ``(III) to verify the identity of the practitioner 
                and that the practitioner is licensed or certified by 
                one or more of the States.
            ``(v) With respect to the licensure or certification of 
        health care practitioners, the provision of services by the 
        out-of-area practitioner in the emergency area is not a 
        violation of the law of the State in which the area is located.
    ``(B) In issuing criteria under subparagraph (A), the Secretary 
shall take into account the need to rapidly enter into arrangements 
under such subparagraph in order to provide health services in 
emergency areas promptly after the emergency begins.
    ``(C) Subparagraph (A) applies with respect to an act or omission 
of an out-of-area practitioner only to the extent that the practitioner 
is not immune from liability for such act or omission under the 
Volunteer Protection Act of 1997.
    ``(D) For purposes of this paragraph, the term `emergency area' 
means a geographic area for which--
            ``(i) the Secretary has made a determination under section 
        319 that a public health emergency exists; or
            ``(ii) a presidential declaration of major disaster has 
        been issued under section 401 of the Robert T. Stafford 
        Disaster Relief and Emergency Assistance Act.''.
    (b) Effective Date.--With respect to paragraph (6) of section 
224(g) of the Public Health Service Act, as added by subsection (a) of 
this section:
            (1) Except as provided in this subsection, an arrangement 
        under subparagraph (A)(iii) of such paragraph (6) is deemed to 
        be in effect for any health professional who, within the 
        meaning of such paragraph--
                    (A) is an employee or contractor of a health center 
                under section 330 of such Act; and
                    (B) served or is serving as an out-of-area 
                practitioner in any emergency area declared as a result 
                of Hurricane Katrina or Hurricane Rita.
            (2) Such paragraph (6) is deemed to have taken effect on 
        August 27, 2005, for purposes of paragraph (1) of this 
        subsection. Such paragraph (6) otherwise takes effect on the 
        date of the enactment of this Act.
            (3) Paragraph (1) of this subsection applies until the 
        expiration of the 48-hour period beginning on the date on which 
        the Secretary of Health and Human Services publishes in the 
        Federal Register a notice that the applicability of such 
        paragraph is being terminated.
Example Output: Amends the Public Health Service Act to deem certain physicians or other licensed or certified health care practitioners to be employees of the Public Health Service for purposes of any civil action that may arise due to services provided in an emergency area by a contractor or an employee of a qualified health center. Provides that such services must be provided under an arrangement with a qualified health center or with a federal agency with responsibility for providing health services in the emergency area.

Example Input: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Regulatory Transparency, Patient 
Access, and Effective Drug Enforcement Act of 2014''.

SEC. 2. SCHEDULING OF SUBSTANCES INCLUDED IN NEW FDA-APPROVED DRUGS.

    Section 201 of the Controlled Substances Act (21 U.S.C. 811) is 
amended by inserting after subsection (h) the following:
    ``(i) Within 45 days of receiving a recommendation from the 
Secretary to add a drug or substance that has never been marketed in 
the United States to a schedule under this title, the Attorney General 
shall, without regard to the findings required by subsection (a) of 
this section or section 202(b), issue an interim final rule, under the 
exception for good cause described in subparagraph (B) of section 
553(b) of title 5, United States Code, placing the drug or substance 
into the schedule recommended by the Secretary. The interim final rule 
shall be made immediately effective under section 553(d)(3) of title 5, 
United States Code.''.

SEC. 3. ENHANCING NEW DRUG DEVELOPMENT.

    Section 302 of the Controlled Substances Act (21 U.S.C. 822) is 
amended by inserting after subsection (g) the following:
    ``(h)(1) A person who submits an application for registration to 
manufacture or distribute a controlled substance in accordance with 
this section may indicate on the registration application that the 
substance will be used only in connection with clinical trials of a 
drug in accordance with section 505(i) of the Federal Food, Drug, and 
Cosmetic Act.
    ``(2) When an application for registration to manufacture or 
distribute a controlled substance includes an indication that the 
controlled substance will be used only in connection with clinical 
trials of a drug in accordance with section 505(i) of the Federal Food, 
Drug, and Cosmetic Act, the Attorney General shall--
            ``(A) make a final decision on the application for 
        registration within 180 days; or
            ``(B) provide notice to the applicant in writing of--
                    ``(i) the outstanding issues that must be resolved 
                in order to reach a final decision on the application; 
                and
                    ``(ii) the estimated date on which a final decision 
                on the application will be made.''.

SEC. 4. REGISTRATION PROCESS UNDER CONTROLLED SUBSTANCES ACT.

    (a) Definitions.--
            (1) Factors as may be relevant to and consistent with the 
        public health and safety.--Section 303 of the Controlled 
        Substances Act (21 U.S.C. 823) is amended by adding at the end 
        the following:
    ``(i) In this section, the phrase `factors as may be relevant to 
and consistent with the public health and safety' means factors that 
are relevant to and consistent with the findings contained in section 
101.''.
            (2) Imminent danger to the public health or safety.--
        Section 304(d) of the Controlled Substances Act (21 U.S.C. 
        824(d)) is amended--
                    (A) by striking ``(d) The Attorney General'' and 
                inserting ``(d)(1) The Attorney General''; and
                    (B) by adding at the end the following:
    ``(2) In this subsection, the phrase `imminent danger to the public 
health or safety' means that, in the absence of an immediate suspension 
order, controlled substances will continue to be distributed or 
dispensed by a registrant who knows or should know through fulfilling 
the obligations of the registrant under this Act, or has reason to 
believe that--
            ``(A) the dispensing is outside the usual course of 
        professional practice;
            ``(B) the distribution or dispensing poses a present or 
        foreseeable risk of adverse health consequences or death due to 
        the abuse or misuse of the controlled substances; or
            ``(C) the controlled substances will continue to be 
        diverted outside of legitimate distribution channels.''.
    (b) Opportunity To Submit Corrective Action Plan Prior to 
Revocation or Suspension.--Subsection (c) of section 304 of the 
Controlled Substances Act (21 U.S.C. 824) is amended--
            (1) by striking the last two sentences;
            (2) by striking ``(c) Before'' and inserting ``(c)(1) 
        Before''; and
            (3) by adding at the end the following:
    ``(2) An order to show cause under paragraph (1) shall--
            ``(A) contain a statement of the basis for the denial, 
        revocation, or suspension, including specific citations to any 
        laws or regulations alleged to be violated by the applicant or 
        registrant;
            ``(B) direct the applicant or registrant to appear before 
        the Attorney General at a time and place stated in the order, 
        but not less than 30 days after the date of receipt of the 
        order; and
            ``(C) notify the applicant or registrant of the opportunity 
        to submit a corrective action plan on or before the date of 
        appearance.
    ``(3) Upon review of any corrective action plan submitted by an 
applicant or registrant pursuant to paragraph (2), the Attorney General 
shall determine whether denial, revocation or suspension proceedings 
should be discontinued, or deferred for the purposes of modification, 
amendment, or clarification to such plan.
    ``(4) Proceedings to deny, revoke, or suspend shall be conducted 
pursuant to this section in accordance with subchapter II of chapter 5 
of title 5, United States Code. Such proceedings shall be independent 
of, and not in lieu of, criminal prosecutions or other proceedings 
under this title or any other law of the United States.
    ``(5) The requirements of this subsection shall not apply to the 
issuance of an immediate suspension order under subsection (d).''.

SEC. 5. REPORT TO CONGRESS ON EFFECTS OF LAW ENFORCEMENT ACTIVITIES ON 
              PATIENT ACCESS TO MEDICATIONS.

    (a) In General.--Not later than 1 year after the date of enactment 
of this Act, the Secretary of Health and Human Services, acting through 
the Commissioner of Food and Drugs and the Director of the Centers for 
Disease Control and Prevention, and in consultation with the 
Administrator of the Drug Enforcement Administration and the Director 
of National Drug Control Policy, shall submit a report to the 
Committees on the Judiciary of the House of Representatives, the 
Committee on Energy and Commerce of the House of Representatives, the 
Committee on the Judiciary of the Senate, and the Committee on Health, 
Education, Labor and Pensions of the Senate identifying--
            (1) obstacles to legitimate patient access to controlled 
        substances;
            (2) issues with diversion of controlled substances; and
            (3) how collaboration between Federal, State, local, and 
        tribal law enforcement agencies and the pharmaceutical industry 
        can benefit patients and prevent diversion and abuse of 
        controlled substances.
    (b) Consultation.--The report under subsection (a) shall 
incorporate feedback and recommendations from the following:
            (1) Patient groups.
            (2) Pharmacies.
            (3) Drug manufacturers.
            (4) Common or contract carriers and warehousemen.
            (5) Hospitals, physicians, and other health care providers.
            (6) State attorneys general.
            (7) Federal, State, local, and tribal law enforcement 
        agencies.
            (8) Health insurance providers and entities that provide 
        pharmacy benefit management services on behalf of a health 
        insurance provider.
            (9) Wholesale drug distributors.
Example Output: Regulatory Transparency, Patient Access, and Effective Drug Enforcement Act of 2014 - Amends the Controlled Substances Act to direct the Attorney General, within 45 days of receiving a recommendation from the Secretary of Health and Human Services (HHS) to add a drug or substance that has never been marketed in the United States to a schedule of controlled substances, to issue an interim final rule under the exception for good cause, placing it into the schedule recommended, effective immediately. Allows a person who submits an application for registration to manufacture or distribute a controlled substance to indicate on the registration application that the substance will be used only in connection with clinical trials of a drug. Requires the Attorney General to: (1) make a final decision on such application within 180 days, or (2) provide written notice to the applicant of the outstanding issues that must be resolved to reach a final decision and the estimated date on which such decision will be made. Defines: (1) "factors as may be relevant to and consistent with the public health and safety," and (2) "imminent danger to the public health or safety." Requires an order to show cause as to why a registration should not be denied, revoked, or suspended to notify the registrant of the opportunity to submit a corrective action plan on or before the date of appearance before the Attorney General. Requires the Attorney General, upon review of any such plan, to determine whether denial, revocation, or suspension proceedings should be discontinued or deferred for purposes of modification or clarification of such plan. Makes these requirements inapplicable to the issuance of an immediate suspension order. Directs the Secretary, acting through the Commissioner of Food and Drugs (FDA) and the Director of the Centers for Disease Control and Prevention (CDC), to identify: (1) obstacles to legitimate patient access to controlled substances; (2) issues with diversion of controlled substances; and (3) how collaboration between federal, state, local, and tribal law enforcement agencies and the pharmaceutical industry can benefit patients and prevent diversion and abuse of controlled substances.

Example Input: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Compassionate Access, Research 
Expansion, and Respect States Act of 2017'' or the ``CARERS Act of 
2017''.

SEC. 2. FEDERALISM IN DRUG POLICY.

    Section 708 of the Controlled Substances Act (21 U.S.C. 903) is 
amended--
            (1) by striking ``No provision'' and inserting the 
        following:
    ``(a) In General.--Except as provided in subsection (b), no 
provision''; and
            (2) by adding at the end the following:
    ``(b) Compliance With State Law.--Notwithstanding any other 
provision of law, the provisions of this title relating to marihuana 
shall not apply to any person acting in compliance with State law, as 
determined by the State, relating to the production, possession, 
distribution, dispensation, administration, laboratory testing, 
recommending use, or delivery of medical marihuana.''.

SEC. 3. EXCLUSION OF CANNABIDIOL FROM DEFINITION OF MARIHUANA.

    Section 102 of the Controlled Substances Act (21 U.S.C. 802) is 
amended--
            (1) in paragraph (16)--
                    (A) by striking ``or cake, or the sterilized'' and 
                inserting ``cake, the sterilized''; and
                    (B) by adding ``, or cannabidiol'' before the 
                period at the end; and
            (2) by adding at the end the following:
            ``(57) The term `cannabidiol' means the substance 
        cannabidiol, as derived from marihuana or the synthetic 
        formulation, that contains not greater than 0.3 percent delta-
        9-tetrahydrocannabinol on a dry weight basis.''.

SEC. 4. CANNABIDIOL DETERMINATION BY STATES.

    Section 201 of the Controlled Substances Act (21 U.S.C. 811) is 
amended by adding at the end the following:
    ``(k) Cannabidiol Determination.--If a person grows or processes 
marihuana for purposes of making cannabidiol in accordance with State 
law, the marihuana shall be deemed to meet the concentration limitation 
under section 102(57), unless the Attorney General determines that the 
State law is not reasonably calculated to comply with section 
102(57).''.

SEC. 5. RESEARCH.

    (a) In General.--Not later than 180 days after the date of 
enactment of this Act, the Secretary of Health and Human Services shall 
terminate the Public Health Service interdisciplinary review process 
described in the guidance entitled ``Guidance on Procedures for the 
Provision of Marijuana for Medical Research'' (issued on May 21, 1999).
    (b) Licenses for Marijuana Research.--Not later than 1 year after 
the date of enactment of this Act, the Attorney General, acting through 
the Drug Enforcement Administration, shall issue not less than 3 
licenses under section 303 of the Controlled Substances Act (21 U.S.C. 
823) to manufacture and distribute marijuana and marijuana-derivatives 
for research approved by the Food and Drug Administration.
    (c) Marijuana Research.--
            (1) In general.--Section 303(f) of the Controlled 
        Substances Act (21 U.S.C. 823(f)) is amended--
                    (A) by redesignating paragraphs (1) through (5) as 
                subparagraphs (A) through (E), respectively;
                    (B) by striking ``(f) The Attorney General'' and 
                inserting ``(f)(1) The Attorney General'';
                    (C) by striking ``Registration applications'' and 
                inserting the following:
    ``(2) Registration applications'';
                    (D) in paragraph (2), as so designated, by striking 
                ``schedule I'' each place that term appears and 
                inserting ``schedule I, except marijuana,'';
                    (E) by striking ``Article 7'' and inserting the 
                following:
    ``(4) Article 7''; and
                    (F) by inserting before paragraph (4), as so 
                designated, the following:
    ``(3)(A) Not later than 180 days after the date of enactment of 
this paragraph, the Secretary shall promulgate regulations that require 
the Secretary to register a practitioner to conduct research on 
marihuana if--
            ``(i) the applicant is authorized to dispense, or conduct 
        research with respect to, controlled substances in schedules 
        II, III, IV, and V under the laws of the State in which the 
        applicant practices; and
            ``(ii) the applicant's research protocol--
                    ``(I) has been reviewed and allowed by--
                            ``(aa) the Secretary under section 505(i) 
                        of the Federal Food, Drug, and Cosmetic Act (21 
                        U.S.C. 355(i)); or
                            ``(bb) the National Institutes of Health or 
                        another Federal agency that funds scientific 
                        research; or
                    ``(II) in the case of nonhuman research that is not 
                federally funded, has been voluntarily submitted by the 
                applicant to, and approved by, the National Institutes 
                of Health.
    ``(B) The Secretary shall grant an application for registration 
under this paragraph unless the Secretary determines that the issuance 
of the registration would be inconsistent with the public interest. In 
determining the public interest, the Secretary shall consider the 
following factors:
            ``(i) The applicant's experience in dispensing, or 
        conducting research with respect to, controlled substances.
            ``(ii) Compliance with applicable Federal or State laws 
        relating to controlled substances.
            ``(iii) Conduct by the applicant that may threaten the 
        public health and safety.''.
            (2) Conforming amendment.--Section 102(16) of the 
        Controlled Substances Act (21 U.S.C. 802(16)) is amended by 
        inserting ``or `marijuana''' after ``The term `marihuana'''.

SEC. 6. PROVISION BY DEPARTMENT OF VETERANS AFFAIRS HEALTH CARE 
              PROVIDERS OF RECOMMENDATIONS AND OPINIONS REGARDING 
              VETERAN PARTICIPATION IN STATE MARIJUANA PROGRAMS.

    Notwithstanding any other provision of law, the Secretary of 
Veterans Affairs shall authorize physicians and other health care 
providers employed by the Department of Veterans Affairs to--
            (1) provide recommendations and opinions to veterans who 
        are residents of States with State marijuana programs regarding 
        the participation of veterans in such State marijuana programs; 
        and
            (2) complete forms reflecting such recommendations and 
        opinions.
Example Output:
Compassionate Access, Research Expansion, and Respect States Act of 2017 or the CARERS Act of 2017 This bill amends the Controlled Substances Act to provide that the Act's regulatory controls and administrative, civil, and criminal penalties do not apply to a person who produces, possesses, distributes, dispenses, administers, tests, recommends, or delivers medical marijuana in compliance with state law. The bill also:  excludes &quot;cannabidiol&quot; (CBD) from the definition of &quot;marijuana&quot;;  limits the concentration of delta-9-tetrahydrocannabinol (THC) in CBD to 0.3 percent on a dry weight basis; and  deems marijuana grown or processed to make CBD, in accordance with state law, to comply with the THC concentration limit unless the Drug Enforcement Administration (DEA) determines state law to be unreasonable.   The bill directs the Department of Health and Human Services (HHS) to terminate the Public Health Service's interdisciplinary review process that is used to evaluate applications for medical marijuana research. The DEA must license manufacturers and distributors of marijuana for medical research; HHS must register practitioners to conduct research; and the Department of Veterans Affairs (VA) must authorize VA health care providers to provide recommendations and opinions to veterans regarding participation in their states' marijuana programs.